Bullish on Jubilant Life Sciences: Daljeet Kohli

PUBLISHED ON: January 19, 2016 | Duration: 17 min, 46 sec

   
loading..
Daljeet Kohli, head of research at IndiaNivesh Securities, says various positives related to Jubilant Life Sciences outweigh the negatives such as currency weakness. The company's pharma business is expected to continue its profitability going ahead and investors may buy the stock for an upside towards Rs 397-400.
ALSO WATCH
जीएसटी घटने से कबाड़ के कारोबार में राहत

................................ Advertisement ................................

................................ Advertisement ................................